The Effect of Venetoclax Combined with Azacitidine on the Clinical Efficacy, Immune Function, and Adverse Reactions in Elderly Patients with Acute Myeloid Leukemia

Zhenfeng Sheng

Show Less

¹ Suzhou Canglang Hospital, Suzhou, Jiangsu, 215000,

JCNR 2025 , 9(6), 188–194; https://doi.org/10.26689/jcnr.v9i6.10948

© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To evaluate the immune function and safety of Venetoclax combined with Azacitidine in the treatment of elderly patients with acute myeloid leukemia (AML). Methods: Sixty-eight elderly AML patients who visited the hospital from January 2021 to December 2024 were selected as samples and randomly divided into two groups. Group A was treated with Venetoclax and Azacitidine, while Group B was treated with Azacitidine alone. Immune indicators, inflammatory factors, tumor markers, and adverse reactions were compared between the two groups. Results: The levels of CD3+, CD4+, and CD8+ in Group A were higher than those in Group B (P < 0.05). The tumor necrosis factor-α (TNF-α) level in Group A was lower than that in Group B, while the interferon-γ (IFN-γ) level was higher (P < 0.05). The levels of cyclooxygenase-2 (COX-2), lactate dehydrogenase (LDH), and vascular endothelial growth factor (VEGF) in Group A were lower than those in Group B (P < 0.05). The adverse reaction rate in Group A was lower than that in Group B (P < 0.05). Conclusion: The combination of Venetoclax and Azacitidine in the treatment of elderly AML patients can improve immune function, inhibit inflammation, delay disease progression, and is safe and efficient.

References

Wang K, Fan B, Zhang Q, et al., 2024, Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in the Treatment of Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy in Adults. Chinese Journal of Experimental Hematology, 32(2): 342–346.

Li Z, Yao J, Yang Y, 2024, Analysis of the Efficacy of Venetoclax Combined with Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia. The Practical Journal of Cancer, 39(6): 957–960.

Leukemia and Lymphoma Group, Hematology Branch of Chinese Medical Association, 2017, Chinese Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (not APL). Chinese Journal of Hematology, 38(3): 177–182.

Long B, Tang H, Meng X, et al., 2024, Observation on the Clinical Effect of Venetoclax Combined with Azacitidine in the Treatment of Elderly Acute Myeloid Leukemia. Big Doctor, 9(21): 22–25.

Chen A, Wang M, Ma X, 2024, Comparison of the Effects of Azacitidine and Decitabine Combined with Venetoclax in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Journal of Clinical Rational Drug Use, 17(9): 120–123.

Shang M, Duan L, He Y, 2024, Effect of Azacitidine Combined with Bcl-2 Inhibitor Venetoclax in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Henan Medical Research, 33(18): 3422–342

Peng P, Zou W, Tang X, et al., 2021, Observation on the Efficacy, Adverse Reactions, and Changes in Hematological Indicators of Azacitidine Combined with CAG Regimen in the Treatment of Elderly Acute Myeloid Leukemia. Journal of Clinical and Experimental Medicine, 20(14): 1482–1485.

Tang G, Wu Y, Zhang X, et al., 2024, Therapeutic Effect of Venetoclax Combined with Other Drugs on Elderly Patients with Acute Myeloid Leukemia. Henan Medical Research, 33(9): 1674–1678.

Ren H, 2024, Clinical Effect of Venetoclax Combined with Azacitidine in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Frontiers in Medicine, 14(11): 27–29.

Wang N, 2022, Efficacy Analysis of Venetoclax Combined with Azacitidine in the Treatment of Relapsed Acute Myeloid Leukemia in the Elderly. Clinical Research, 30(11): 80–83.

Previous article in this issue

Next article in this issue